Research and Development Expense (TTM) Chart

Historical Research and Development Expense (TTM) Data

View and export this data back to 2007. Start Trial.
Date Value
September 30, 2026 32.08M
June 30, 2026 29.28M
March 31, 2026 26.94M
December 31, 2025 24.61M
September 30, 2025 24.38M
June 30, 2025 22.93M
March 31, 2025 21.04M
December 31, 2024 19.06M
September 30, 2024 16.26M
June 30, 2024 14.55M
March 31, 2024 13.17M
December 31, 2023 13.11M
September 30, 2023 11.70M
June 30, 2023 10.07M
March 31, 2023 9.483M
December 31, 2022 7.839M
September 30, 2022 7.44M
June 30, 2022 8.132M
March 31, 2022 8.333M
December 31, 2021 8.765M
September 30, 2021 10.01M
June 30, 2021 9.862M
March 31, 2021 9.335M
December 31, 2020 8.31M
September 30, 2020 6.992M
Date Value
June 30, 2020 6.429M
March 31, 2020 6.674M
December 31, 2019 7.90M
September 30, 2019
June 30, 2019
March 31, 2019
December 31, 2018
September 30, 2018 3.781M
June 30, 2018 3.060M
March 31, 2018 3.129M
December 31, 2017 3.496M
September 30, 2017
June 30, 2017
March 31, 2017
December 31, 2016
September 30, 2016 1.635M
June 30, 2016 1.038M
March 31, 2016 0.8746M
December 31, 2015 0.9576M
September 30, 2015 1.223M
June 30, 2015 1.525M
March 31, 2015 2.242M
December 31, 2014 3.644M
September 30, 2014 4.252M
June 30, 2014 4.978M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

View Research and Development Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (TTM) Benchmarks

View Research and Development Expense (TTM) Benchmarks
Start Trial
Arrowhead Pharmaceuticals, Inc. 929.60M
Nektar Therapeutics 148.61M
Fortress Biotech, Inc. 2.656M
ACADIA Pharmaceuticals, Inc. 319.46M
Alnylam Pharmaceuticals, Inc. 1.559B